Filtering

DOP61 Tofacitinib, an oral, small-molecule Janus kinase inhibitor, in the treatment of ulcerative colitis: Analysis of an open-label, long-term extension study with up to 5.9 years of treatment

ECCO'20 Vienna

Year: 2020
Authors:

G.R. Lichtenstein1, E.V. Loftus Jr2, S.C. Wei3, A.O. Damião4, D. Judd5, N. Lawendy5, G. Chan5, H. Zhang5, W. Wang5, A.J. Thorpe5, S. Bloom6

1Division of Gastroenterology, Perelman School of Medicine at University of Pennsylvania, Philadelphia, USA, 2Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA, 3Department of Internal Medicine, National Taiwan University Hospital and College of Medicine, Taipei, Taiwan, Province of China, 4Department of Gastroenterology, University of São Paulo School of Medicine, São Paulo, Brazil, 5Pfizer Inc., Collegeville, PA, USA, 6University College London Hospitals NHS Foundation Trust, London, UK, UK

DOP62 Morbidity after primary ileocecal resection for Crohn’s disease in the years of biologics: Lesson learned over 631 patients exclusively treated in a tertiary centre

ECCO'20 Vienna

Year: 2020
Authors:

M. Rottoli1, M. Tanzanu1, G. Vago1, A. Belvedere1, D. Parlanti1, P. Pezzuto1, S. Bosi1, F. Caputo1, F. Rizzello2, P. Gionchetti2, G. Poggioli1

1Surgery of the Alimentary Tract, Sant’Orsola Hospital, Alma Mater Studiorum University of Milan, Bologna, Italy, 2Inflammatory Bowel Disease Unit, Sant’Orsola Hospital, Alma Mater Studiorum University of Milan, Bologna, Italy

DOP63 Efficacy and safety of iron carboxymaltose on chronic fatigue in patients with inflammatory bowel disease: a randomised controlled trial

ECCO'20 Vienna

Year: 2020
Authors:

G. Fiorino1, M. Allocca1, D. Gilardi1, M. Alfieri1, P. Danieli1, F. Furfaro1, G. Roda1, L. Loy1, A. Zilli1, S. Radice1, L. Peyrin-Biroulet2, S. Danese1

1Department of Gastroenterology, IBD Center, Humanitas Research Hospital, Rozzano, Italy, 2Inserm U954, Nancy University Hospital, IBD Unit, Nancy, France

DOP64 Discovery of highly selective small-molecule oral inhibitors of integrin α4β7 for the treatment of inflammatory bowel diseases

ECCO'20 Vienna

Year: 2020
Authors:

J. WONG1, M. Bursavich2, N. Blanco1, A. Camblin1, L. Cappellucci1, R. Cohen1, D. Cui3, M. Krumpoch1, C. Zhong2, K. Hahn2, D. Lee3, B. Lippa2, F.Y. Lin4, A. Lugovsky5, M. McShea4, S. Mostafavi4, T. Moy1, A. Sullivan6, D. Troast2, L. Wang1, B. Rogers2

1Department of Biology, Morphic Therapeutic, Waltham, USA, 2Department of Chemistry, Morphic Therapeutic, Waltham, USA, 3Department of Drug Metabolism and Pharmacokinetics, Morphic Therapeutic, Waltham, USA, 4Department of Structural Biology, Morphic Therapeutic, Waltham, USA, 5Department of Development, Morphic Therapeutic, Waltham, USA, 6Department of Translational Sciences, Morphic Therapeutic, Waltham, USA

DOP65 Mirikizumab regulates genes involved in anti-TNF resistance and ulcerative colitis disease activity

ECCO'20 Vienna

Year: 2020
Authors:

B. Steere1, J. Schmitz1, N. Powell2, R. Higgs1, K. Gottlieb1, Y. Liu1, B. Jia1, J.L. Tuttle3, W.J. Sandborn4, B.E. Sands5, V. Krishnan1

1Eli Lilly and Company, Lilly Biomedicines, Indianapolis IN, USA, 2Centre for Inflammation Biology and Cancer Immunology, King’s College London, London, UK, 3Lilly Biotechnology Center, Eli Lilly and Company, Sand Diego, CA, USA, 4Division of Gastroenterology, University California San Diego, La Jolla, CA, USA, 5Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, NY, USA

DOP66 A CEACAM5 small peptide restores the suppressive activity of CD8 + T cells in patients with Crohn’s disease

ECCO'20 Vienna

Year: 2020
Authors:

G. Roda PhD1, D. Dunkin2, C. Correale1, S. Vetrano1, F. Merlino3, L. Marinelli3, E. Novellino3, L. Mayer4, G. Yeretssian5,6, S. Danese1

1Humanitas Research Hospital, IBD Center, Milano, Italy, 2Icahn School of Medicine at Mount Sinai, Division of Pediatric Gastroenterology and The Mindich Child Health and Development Institute, New York, USA, 3Department of Pharmacy, University of Naple, Naple, Italy, 4Clinical Immunology, Icahn School of Medicine at Mount Sinai, New York, USA, 5The Leona M. and Harry B. Helmsley Charitable Trus, The Leona M. and Harry B. Helmsley Charitable Trust, New York, USA, 6Icahn School of Medicine at Mount Sinai, The Precision Immunology Institute, New York, USA

DOP67 CKD-506, a selective histone deacetylase (HDAC) 6 inhibitor, ameliorates colitis through regulation of NF-kB and AP-1 signalling pathway

ECCO'20 Vienna

Year: 2020
Authors:

J. Shin1, N. Ha1, D. Bae1, Y.J. Lee1, Y.I. Choi1, K.H. Ryu1, G.S. Youn2, J. Park2

1Department of Non-clinical Study, Chong Kun Dang Pharm. Research Institute, Youngin-si, Korea Republic of, 2Department of Biomedical Science, Hallym University, Chuncheon, Korea Republic of

DOP68 Thiomyristoyl ameliorates colitis by blocking the differentiation of Th17 cells via STAT3/IL-6 signal pathway

ECCO'20 Vienna

Year: 2020
Authors:

Y. XU1, M. zhang2, G. Xu2, X. Zou2

1Department of Gastroenterology, Nanjing Medical University Affiliated Drum Tower Clinical Medical College, Nanjing, China, 2Department of Gastroenterology, Nanjing Drum Tower Hospital Clinical College of Nanjing Medical University, Nanjing, China

DOP69 Tofacitinib in ulcerative colitis: Early ‘real-world’ experience from four UK tertiary centres

ECCO'20 Vienna

Year: 2020
Authors:

D. Chee1, S. Honap2, T.P. Chapman3, A.J. Kent4, M. Patel4, B. Hayee4, P. Dubois4, L. Medcalf4, E. Sharma5, Y. Begum5, S. Ray2, J. Kennedy3, S. Cripps6, C. Elworthy7, A. Walsh3, J.R. Goodhand1, T. Ahmad1, J. Satsangi3, N.A. Kennedy1, P. Irving2, LEO (London, Exeter, Oxford) Consortium - Travis S, Brain O, Palmer R

1Department of Gastroenterology, Royal Devon and Exeter NHS Foundation Trust, Exeter, UK, 2Department of Gastroenterology, Guy’s and St Thomas’ NHS Foundation Trust, London, UK, 3Translational Gastroenterology Unit, John Radcliffe Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, UK, 4Department of Gastroenterology, King’s College Hospital NHS Foundation Trust, London, UK, 5Department of Pharmacy, Guy’s and St Thomas’ NHS Foundation Trust, London, UK, 6Pharmacy Department, John Radcliffe Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, UK, 7Department of Pharmacy, Royal Devon and Exeter NHS Foundation Trust, Exeter, UK

DOP70 High-dimensional analysis reveals a novel signature for IL-17 producing CD8 T cells in inflammatory bowel disease

ECCO'20 Vienna

Year: 2020
Authors:

A.M. Globig1, P. Otto-Mora1, A. Hipp1, M. Heeg2, H. Schwacha1, V. Tomov3, R. Thimme1, P. Hasselblatt1, B. Bengsch1

1Department of Medicine II, Gastroenterology, Hepatology, Endocrinology, and Infectious Diseases, University Medical Center Freiburg, Freiburg, Germany, 2Institute for Immunodeficiency, Center for Chronic Immunodeficiency, University Medical Center Freiburg, Freiburg, Germany, 3Division of Gastroenterology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA

DOP71 Efficacy, safety, and tolerability of ustekinumab in paediatric patients with moderately to severely active Crohn’s disease: Results from, UniStar, a phase 1 study

ECCO'20 Vienna

Year: 2020
Authors:

J. Rosh1, D. Turner2, A. Griffiths3, D. Jacobstein4, O. Adedokun5, L. Padgett5, N. Terry5, C. O’Brien5, J. Hyams6

1Department of Pediatrics, Goryeb Children’s Hospital/Atlantic Health, Morristown, NJ, USA, 2Department of Pediatrics, Shaare Zedek Medical Center, Jerusalem, Israel, 3SickKids Hospital, Toronto, ON, Canada, 4Former Employee of Janssen Research and Development, LLC, Current Employee of Provention Bio, Research and Development, Horsham, PA, USA, 5Janssen Research and Development, LLC, Research and Development, Horsham, PA, USA, 6Department of Pediatrics, Connecticut Children’s Medical Center, Hartford, CT, USA

DOP72 Safety, tolerability and efficacy of anti-TL1A antibody PF-06480605 in treatment of ulcerative colitis: The open-label, multicentre, Phase 2a TUSCANY study

ECCO'20 Vienna

Year: 2020
Authors:

S. Danese1, M. Klopocka2, E.J. Scherl3, J. Romatowski4, J.R. Allegretti5, E. Peeva6, M.S. Vincent6, U. Schoenbeck7, L. Xi6, Z. Ye6, M. Hassan-Zahraee6, N. Rath8, G. Li8, S. Neelakantan6, C. Banfield6, C. Lepsy9, D. Chandra6, K.E. Hung6

1Department of Gastroenterology, IBD Center, Humanitas Research Hospital, Milan, Italy, 2Department of Gastroenterology and Nutrition, Nicolaus Copernicus University in Toruń, Collegium Medicum, Bydgoszcz, Poland, 3Division of Gastroenterology and Hepatology, Jill Roberts Center for IBD, Weill Cornell Medicine, New York, NY, USA, 4Internal Medicine and Gastroenterology Department, J. Sniadecki’s Regional Hospital, Białystok, Poland, 5Division of Gastroenterology, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA, 6Pfizer Inc., Cambridge, MA, USA, 7Pfizer Inc., New York, NY, USA, 8Pfizer Inc., Collegeville, PA, USA, 9Pfizer Inc., Andover, MA, USA

DOP73 Efficacy and safety of escalation to tofacitinib 10 mg BID for patients with UC following loss of response on 5 mg BID maintenance therapy: Results from OCTAVE open-label, long-term extension study

ECCO'20 Vienna

Year: 2020
Authors:

B.E. Sands1, A.C. Moss2, A. Armuzzi3, J.K. Marshall4, J.O. Lindsay5, W.J. Sandborn6, S. Danese7, M. Zeroncio8, I. Modesto9, L. Salese10, N. Lawendy10, H. Zhang10, C. Su10

1Icahn School of Medicine at Mount Sinai, Dr. Henry D. Janowitz Division of Gastroenterology, New York, NY, USA, 2Division of Gastroenterology, Beth Israel Deaconess Medical Center, Boston, MA, USA, 3IBD Unit, Fondazione Policlinico Universitario A. Gemelli IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy, 4Division of Gastroenterology, Department of Medicine, Farncombe Family Digestive Health Research Institute, McMaster University, Hamilton, Ontario, Canada, 5Department of Gastroenterology, The Royal London Hospital, Barts Health NHS Trust, London, UK, 6Division of Gastroenterology, University of California - San Diego, La Jolla, CA, USA, 7IBD Center, Department of Gastroenterology, Humanitas Research Hospital, Rozzano, Milan, Italy, 8Brazilian IBD Study Group, Avenida Brigadeiro Faria Lima, São Paulo, Brazil, 9Pfizer Inc., New York, NY, USA, 10Pfizer Inc., Collegeville, PA, USA

DOP74 Effectiveness of dose escalation in Crohn’s disease patients with insufficient response to standard-dose subcutaneous ustekinumab maintenance therapy: A multicentre international cohort study

ECCO'20 Vienna

Year: 2020
Authors:

U. Kopylov1, J. Hanzel2, C. Liefferinckx3, D. De Marco4, N. Imperatore5, N. Plevris6, I. Baston-Rey7, R. Harris8, M. Truyens9, V. Domislovic10, S. Vavricka11, V. Biemans12,13, S. Myers14, S. Shaji14, S. Ben-Horin1, Y. González Lama15, C. Gilletta16, A. Bar-Gil Shitrit17, Z. Zelinkova18, R. Weishof19, D. Storan20, E. Zittan21, D. Franchimont3, A. Cremer3, W. Afif4, F. Castiglione5, C. Lees7, M. Barrero de Acosta7, T. Lobaton9, G. Doherty20, Z. Krznaric10, M. Pierik12, F. Hoentjen13, D. Drobne2

1Sheba Medical Center, Ramat Gan and Sackler Medical School, Tel Aviv, Israel, Department of Gastroenterology, Ramat Gan, Israel, 2Department of Gastroenterology, University Medical Centre Ljubljana, Ljubliana, Slovenia, 3Department of Gastroentrerology, Hôpital Erasme, ULB, Brussels, Belgium, Department of Gastroenterology, 4McGill University Health Center, Montreal, Canada, 5School of Medicine Federico II of Naples, Department of Clinical Medicine and Surgery, Department of Gastroenterology, Naples, Italy, 6Western General Hospital, Edinburgh IBD Unit, Edinburgh, UK, 7Servicio de Aparato Digestivo, Hospital Clínico Universitario de Santiago de Compostela, Unidad EII, Santiago de Compostela, Spain, 8University Hospital Southampton NHS Foundation Trust, Department of Gastroenterology, Southampton, UK, 9Department of Gastroenterology, Ghent University Hospital, Ghent, Belgium, 10Department of Gastroenterology and Hepatology, University Hospital Centre Zagreb, Zagreb, Croatia, 11Center for Gastroenterology and Hepatology, Zurich, Switzerland, 12Division of Gastroenterology and Hepatology, Maastricht University Medical Center, Department of Internal Medicine, Maastricht, The Netherlands Antilles, 13Department of Gastroentrology, Radboud University Medical Center, Nijmegen, The Netherlands Antilles, 14IBD Unit, Hull University Teaching Hospitals NHS Trust, Hull, UK, 15Gastroenterology and Hepatology Department, Hospital Universitario Puerta de Hierro, IBD Unit, Madrid, Spain, 16CHU Toulouse Rangueil, Service de Gastroentérologie et Nutrition, Toulouse, France, 17Shaare Zedek Medical Center Affiliated with the Medical School, Hebrew University, IBD MOM Unit, Digestive Diseases Institute, Jerusalem, Israel, 18Department of Gastroenterology and Gastrointestinal Endoscopy, St Michael’s Hospital, Bratislava, Slovakia, 19Rambam Health Care Campus, Haifa, Israel, †Bruce Rappaport School of Medicine, Technion-Israel Institute of Technology, Gastroenterology, Haifa, Israel, 20St. Vincent’s University Hospital and School of Medicine, University College Dublin, Centre for Colorectal Disease, Dublin, Ireland, 21Emek Medical Center, Ellen and Pinchas Mamber Institute of Gastroenterology and Liver Diseases, Afula, Israel

DOP75 Efficacy of tofacitinib dose escalation to 10 mg BID in patients with UC after completing maintenance therapy in remission and losing response: Data from OCTAVE open-label, long-term extension study

ECCO'20 Vienna

Year: 2020
Authors:

D.T. Rubin1, M.C. Dubinsky2, J. Panés3, D.C. Wu4, N. Lawendy5, X. Guo5, C. Lai6, K. Kwok7, C. Su5, L. Salese5

1Inflammatory Bowel Disease Center, University of Chicago Medicine, Chicago, IL, USA, 2Icahn School of Medicine at Mount Sinai, New York, NY, USA, 3Hospital Clínic de Barcelona, IDIBAPS, CIBERehd, Barcelona, Spain, 4Division of Gastroenterology, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taipei, Taiwan, Province of China, 5Pfizer Inc., Collegeville, PA, USA, 6Pfizer Inc., New Taipei City, Taiwan, Taiwan, Province of China, 7Pfizer Inc., New York, NY, USA

DOP76 Corticosteroid sparing effects of ustekinumab therapy for ulcerative colitis through 2 years: UNIFI long-term extension

ECCO'20 Vienna

Year: 2020
Authors:

L. Peyrin-Biroulet1, W. Sandborn2, B. Sands3, E. Scherl4, C. Marano5, C. O’Brien5, H. Zhang6, J. Johanns6, Y. Zhou6, M. Abreu7, R.P. Arasaradnam8, D.S. Rowbotham9, R.W.L. Leong10, S. Danese11, UNIFI Investigators

1Department of Gastroenterology, Nancy University Hospital, Nancy, France, 2Department of Gastroenterology, University of California - San Diego, La Jolla, USA, 3Department of Gastroenterology, Icahn School of Medicine at Mount Sinai, La Jolla, USA, 4Weill Cornell Medical Center, Jill Roberts Center for Inflammatory Bowel Disease, New York, USA, 5Department of Immunology, Janssen Research and Development- LLC, Spring House, USA, 6Department of Clinical Biostats, Janssen Research and Development- LLC, Spring House, USA, 7Department of Gastroenterology, University of Miami Miller School of Medicine, Miami, USA, 8Warwick Medical School, Department of Gastroenterology, University Hospital Coventry, Coventry, UK, 9Department of Gastroenterology and Hepatology, Auckland City Hospital, Auckland, New Zealand, 10Department of Gastroenterology, The University of New South Wales and Macquarie University, Sydney, Australia, 11Department of Gastroenterology, Humanitas Research Hospital, Milan, Italy

DOP77 Ustekinumab is associated with better effectiveness outcomes when compared with vedolizumab in Crohn’s disease patients with prior anti-TNF failure: comparative effectiveness study from the ICC Registry

ECCO'20 Vienna

Year: 2020
Authors:

V. Biemans drs1, J. van der Woude2, G. Dijkstra3, A. van der Meulen- de Jong4, M. Löwenberg5, N. de Boer6, B. Oldenburg7, N. Srivastava8, J. Jansen9, A. Bodelier10, R. West11, A. de Vries2, J. Haans12, D. de Jong13, F. Hoentjen13, M. Pierik12, on behalf of the Dutch Initiative on Crohn and Colitis (ICC)

1Radboud University Nijmegen Medical Centre, Maastricht University Medical Centre, Department of Gastroenterology, Nijmegen, The Netherlands, Department of Gastroenterology and Hepatology, 2Erasmus Medical Centre, Rotterdam, The Netherlands, 3Department of Gastroenterology and Hepatology, University Medical Centre Groningen, University of Groningen, Groningen, The Netherlands, 4Department of Gastroenterology and Hepatology, Leiden University Medical Centre, Leiden, The Netherlands, 5Department of Gastroenterology and Hepatology, Amsterdam University Medical Centre, Academic Medical Centre, Amsterdam, The Netherlands, 6Department of Gastroenterology and Hepatology, Amsterdam University Medical Centre, Vrije Universiteit, Amsterdam Gastroenterology and Metabolism Research Institute, Amsterdam, The Netherlands, 7Department of Gastroenterology and Hepatology, University Medical Centre Utrecht, Utrecht, The Netherlands, 8Department of Gastroenterology and Hepatology, Haaglanden Medical Centre, the Hague, The Netherlands, 9Department of Gastroenterology and Hepatology, Onze Lieve Vrouwe Gasthuis, Amsterdam, The Netherlands, 10Department of Gastroenterology and Hepatology, Amphia Hospital, Breda, The Netherlands, 11Department of Gastroenterology and Hepatology, Franciscus Gasthuis and Vlietland, Rotterdam, The Netherlands, 12Department of Gastroenterology and Hepatology, Maastricht University Medical Centre, Maastricht, The Netherlands, 13Department of Gastroenterology and Hepatology, Radboud University Medical Centre, Nijmegen, The Netherlands

DOP78 Intestinal surgery rates in ulcerative colitis and Crohn’s disease in the era of biologics: A Danish Nationwide Register Study from 2003 to 2016

ECCO'20 Vienna

Year: 2020
Authors:

K. Vadstrup1, S. Alulis2, A. Borsi3, J. Olsen4, T.R. Jørgensen5, P. Munkholm6, N. Qvist7

1Janssen-Cilag, Medical Affairs, Birkerød, Denmark, 2Janssen-Cilag, External Affairs, Birkerød, Denmark, 3Janssen-Cilag, External Affairs, High Wycombe, UK, 4Incentive, Evidence Generation, Holte, Denmark, 5LEO Pharma, Global Public Affairs, Copenhagen, Denmark, 6North Zealand University Hospital, Gastroenterology Department, Frederikssund, Denmark, 7Odense University Hospital, Surgical Department A and IBD Care, Odense, Denmark

DOP79 Dose escalation of upadacitinib in Crohn’s disease patients with an inadequate response: Data from the randomised CELEST study

ECCO'20 Vienna

Year: 2020
Authors:

W. Sandborn MD1, J. Panés2, L. Peyrin-Biroulet3, E. Louis4, S. Greenbloom5, W. Zhou6, Q. Zhou7, J. Liu8, A.P. Lacerda6

1Division of Gastroenterology, University of California San Diego, La Jolla, USA, 2Inflammatory Bowel Diseases Unit, Hospital Clínic Barcelona- IDIBAPS, CIBERehd, Barcelona, Spain, 3Department of Gastroenterology, University of Lorraine, Nancy, France, 4Department of Gastroenterology, University Hospital CHU of Liège, Liège, Belgium, 5Department of Gastroenterology, Toronto Digestive Disease Associates, Toronto, Canada, 6Global Pharmaceutical Research and Development, AbbVie Inc., North Chicago, USA, 7Data and Statistical Sciences, AbbVie Inc., North Chicago, USA, 8Pharmacovigilance and Patient Safety, AbbVie Inc., North Chicago, USA

DOP80 Effectiveness of ustekinumab and vedolizumab in patients with Crohn’s disease refractory to anti-tumour necrosis factor: A multi-centre comparative study

ECCO'20 Vienna

Year: 2020
Authors:

H. Alric1, A. Amiot2, J. Kirchgesner3, X. Tréton4, M. Allez5, Y. Bouhnik4, L. Beaugerie3, F. Carbonnel1, A. Meyer1

1Hôpital Bicêtre, Service de gastro-entérologie, Le Kremlin-Bicêtre, France, 2Hôpital Henri Mondor, Service de gastro-entérologie, Créteil, France, 3Hôpital Saint-Antoine, Service de gastro-entérologie, Paris, France, 4Hôpital Beaujon, Service de gastro-entérologie et assistance nutritive, Clichy, France, 5Hôpital Saint-Louis, Service de gastro-entérologie, Paris, France